Search Results
Nov 16, 2025, 22:29 ET Taiyo Holdings推出次世代半導體封裝材料FPIM (TM) Series 成功於12吋晶圓上首次實現CD 1.6微米三層RDL結構
View original content:https://www.prnewswire.com/apac/zh/news-releases/taiyo-holdingsfpim-tm-series-12cd-1-6rdl-302616541.html
More news about: Taiyo Holdings Co. Ltd.
Nov 15, 2025, 13:38 ET Die Fondazione Telethon gibt bekannt, dass der CHMP eine positive Stellungnahme zu Waskyra™ abgegeben hat, einer Gentherapie zur Behandlung des Wiskott-Aldrich-Syndroms (WAS)
Gentherapie für das Wiskott-Aldrich-Syndrom Waskyra besteht aus einer einmaligen Verabreichung autologer CD34+-hämatopoetischer Stamm- und Vorläuferzellen, die mit einem lentiviralen Vektor transduziert wurden, der das WAS-Gen kodiert. Nach
More news about: Fondazione Telethon
Nov 15, 2025, 13:30 ET La Fondazione Telethon annonce l'avis positif du CHMP pour Waskyra™, une thérapie génique pour le traitement du syndrome de Wiskott-Aldrich (WAS)
Wiskott-Aldrich Waskyra consiste en une administration unique de cellules souches et progénitrices hématopoïétiques CD34+ autologues qui ont été transduites avec un vecteur lentiviral codant pour le gène WAS. Une fois corrigées, les cellules souches
More news about: Fondazione Telethon
Nov 14, 2025, 10:32 ET La Fondazione Telethon anuncia la opinión positiva del CHMP sobre Waskyra™
Wiskott-Aldrich Waskyra consiste en una única administración de células madre y progenitoras hematopoyéticas CD34+ autólogas transducidas con un vector lentiviral que codifica el gen del síndrome de Wiskott-Aldrich (WAS). Una vez corregido
More news about: Fondazione Telethon
Nov 14, 2025, 10:24 ET Fondazione Telethon annuncia il parere positivo del CHMP per Waskyra™, terapia genica per il trattamento della sindrome di Wiskott-Aldrich (WAS)
Waskyra consiste in una singola somministrazione di cellule staminali e progenitrici ematopoietiche autologhe CD34+, trasdotte con un vettore lentivirale che codifica per il gene WAS. Una volta corrette, le cellule staminali vengono reinfuse nel paziente, che viene
More news about: Fondazione Telethon
Nov 14, 2025, 10:03 ET Fondazione Telethon announces CHMP positive opinion for Waskyra™, a gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS)
autotemcel) gene therapy for Wiskott-Aldrich syndrome Waskyra consists of a single administration of autologous CD34+ hematopoietic stem and progenitor cells that have been transduced with a lentiviral vector encoding the WAS gene. Once corrected,
More news about: Fondazione Telethon
Nov 14, 2025, 08:52 ET CD Valet Highlights Seasonal Promotions to Help Savers' Money Go Further
About CD Valet CD Valet is a digital marketplace that connects consumers with top CD rates from banks and credit unions nationwide and enables financial institutions to efficiently and cost-effectively attract retail deposits. With CD Valet, banks and
More news about: CD Valet
Nov 13, 2025, 22:00 ET 發掘年輕創作者！「pixiv台灣學生插畫比賽2025」徵件開始
https://comic.tut.edu.tw/） 國立高雄科技大學文化創意產業系（http://cci.nkust.edu.tw/cd/） 國立臺北商業大學商業設計管理系（
More news about: pixiv Inc.
Nov 13, 2025, 08:00 ET RegCell Announces Two Peer-Reviewed Publications Supporting its Robust Scientific Foundation on Antigen-Specific Tolerance to Treat Autoimmune Diseases
expression and established Treg-specific epigenetic programs from conventional T cells to achieve targeted immunosuppression. Both naïve and effector/memory CD4+ T cells were induced into Tregs that closely resemble natural Tregs in function and stability, effectively suppressing inflammatory bowel disease and
More news about: RegCell, Inc.
Nov 13, 2025, 01:00 ET Taiyo Holdings Launches Next-generation Semiconductor-packaging Material "FPIM (TM) Series," Its First Successful Formation of 3-layer RDL with CD 1.6 Micrometers on 12-inch Wafer
carried out. Each wiring pitch achieved the target dimensions as follows: CD (*4) 1.6 micrometers for the RDL1 layer on the wafer, CD 2.0 micrometers (with a via center-to-center pitch of CD 4.0 micrometers) for the via layer, and CD 1.6 micrometers for the RDL2 layer. These values are extremely close to
More news about: Taiyo Holdings Co. Ltd.
Nov 12, 2025, 16:15 ET Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
were observed in at least two participants after a single 4-hour treatment. Increases were noted in total T cell numbers, CD8 and CD4 T cell subsets, and tumor specific T cells (CD137 +ve) in participants following Hemopurifier treatment without a consistent pattern in terms of timing of improvement.
More news about: Aethlon Medical, Inc.
Nov 12, 2025, 09:00 ET Helm Marks 10 Years With Release of Version 4
This release simplifies and enhances the safety of deploying and managing applications at scale, addressing challenges such as CI/CD complexity, security, and multi-cluster operations. The target audience includes platform engineers, DevOps teams, Kubernetes
More news about: CNCF
Nov 12, 2025, 03:00 ET AbolerIS Pharma Announces Publication in Molecular Therapy Cell Press Journal of New Preclinical Results Supporting Mechanism of Action of ABO21009, a First-in-Class Anti-CD45RC Antibody, Currently in Phase 1
first detailed description of how anti-CD45RC antibodies selectively deplete disease-driving immune cells while sparing T regulatory cells. "We are pleased to be recognized by Molecular Therapy for our groundbreaking work targeting CD45RC. These results define the mechanism
More news about: AbolerIS Pharma
Nov 11, 2025, 17:31 ET Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveInsight
(IVIG), and complement inhibitors, reflecting the central role of the complement pathway in its pathogenesis. Additional treatment options include anti-CD20 monoclonal antibodies, proteasome inhibitors, and IL-6 inhibitors. In severe or early-onset cases, surgical splenectomy, splenic embolization, or splenic
More news about: DelveInsight Business Research, LLP
Nov 11, 2025, 13:53 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
Lu AG22515 (anti-CD40L blocker)11
More news about: H. Lundbeck A/S
Nov 11, 2025, 13:46 ET Cloud FinOps Market to Reach USD 27,671.34 million by 2032 at 10.8% CAGR - Credence Research
applications, which can cut waste by 30%. Platforms like those from CloudBolt leverage machine learning for predictive forecasting, integrating with CI/CD pipelines to embed financial controls in development. This trend is gaining traction in AI-intensive sectors, where workload variability
More news about: Credence Research Inc.
Nov 11, 2025, 13:38 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
Lu AG22515 (anti-CD40L blocker)11
More news about: H. Lundbeck A/S
Nov 11, 2025, 13:11 ET Abstracta lança Abstracta Intelligence, uma nova plataforma de entrega baseada em IA
— sistemas, contexto e pessoas. Ela conecta ferramentas e ambientes de entrega (Jira, Postman, Playwright/Selenium, pipelines de CI/CD, AS/400, sistemas bancários core etc.) a uma camada de compreensão impulsionada por IA (RAG + prompts) e ao conhecimento de desenvolvedores e equipes
More news about: Abstracta
Nov 11, 2025, 13:07 ET Abstracta lanza Abstracta Intelligence, una nueva plataforma de entrega impulsada por IA
fundamentales: sistemas, contexto y personas. Vincula las herramientas y los entornos de entrega (Jira, Postman, Playwright/Selenium, estructuras productivas CI/CD, AS/400, sistemas bancarios centrales, etc.) con una capa de comprensión impulsada por IA (RAG + prompts) y el conocimiento de los desarrolladores y
More news about: Abstracta
Nov 11, 2025, 12:00 ET Abstracta Launches Abstracta Intelligence, a New AI-Powered Delivery Platform
fundamental layers—systems, context, and people. It links delivery tools and environments (Jira, Postman, Playwright/Selenium, CI/CD pipelines, AS/400, core banking systems, etc.) with an AI-powered comprehension layer (RAG + prompts) and the knowledge of developers and quality teams.
More news about: Abstracta
Nov 11, 2025, 10:01 ET XTEND WINS A MULTI-MILLION-DOLLAR U.S. DEPARTMENT OF WAR (DOW) CONTRACT TO DEVELOP AND DELIVER AI-ENABLED AFFORDABLE CLOSE QUARTER MODULAR ONE-WAY ATTACK DRONE (OWA) KIT
Office of the Assistant Secretary of War (OASW) for Special Operations / Low-Intensity Conflict (SO/LIC) Capability Development & Innovation (CD&I) Directorate competitively awarded XTEND Reality Inc., a multi-million-dollar Firm Fixed Price Contract to rapidly develop and deliver Affordable
More news about: XTEND
Nov 11, 2025, 10:01 ET Business Travel Market to Reach $2,095.4 Billion, Globally, by 2031 at 9.5% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/checkout-final/04266cdaf15757ce2cd7f28ff833f047 The food & lodging segment to rule
More news about: Allied Market Research
Nov 11, 2025, 10:00 ET XTEND WINS A MULTI-MILLION-DOLLAR U.S. DEPARTMENT OF WAR (DOW) CONTRACT TO DEVELOP AND DELIVER AI-ENABLED AFFORDABLE CLOSE QUARTER MODULAR ONE-WAY ATTACK DRONE (OWA) KIT
Office of the Assistant Secretary of War (OASW) for Special Operations / Low-Intensity Conflict (SO/LIC) Capability Development & Innovation (CD&I) Directorate competitively awarded XTEND Reality Inc., a multi-million-dollar Firm Fixed Price Contract to rapidly develop and deliver Affordable
More news about: XTEND
Nov 11, 2025, 10:00 ET XTEND WINS A MULTI-MILLION-DOLLAR U.S. DEPARTMENT OF WAR (DOW) CONTRACT TO DEVELOP AND DELIVER AI-ENABLED AFFORDABLE CLOSE QUARTER MODULAR ONE-WAY ATTACK DRONE (OWA) KIT
Office of the Assistant Secretary of War (OASW) for Special Operations / Low-Intensity Conflict (SO/LIC) Capability Development & Innovation (CD&I) Directorate competitively awarded XTEND Reality Inc., a multi-million-dollar Firm Fixed Price Contract to rapidly develop and deliver Affordable
More news about: XTEND
Nov 11, 2025, 09:00 ET Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
fibroblast-to-myofibroblast transdifferentiation via upregulation of extracellular matrix and α-smooth muscle actin (α-SMA), as demonstrated in the study "CD39 Fibroblasts Enhance Myofibroblast Activation by Promoting IL-11 Secretion in Hypertrophic Scars" in Journal of Investigative Dermatology (2022). Targeting
More news about: Mabwell